ABVC BioPharma, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023; unaudited consolidated results. ABVC is a clinical-stage biopharmaceutical and medical-device developer, with additional contract development and manufacturing services through BioKey. Share and per-share figures reflect the July 2023 1-for-10 reverse split.
Financial performance and position
| Metric | Q3 2023 / Sept. 30, 2023 | Comparable period / Dec. 31, 2022 |
|---|---|---|
| Revenue | $15,884 for Q3; $150,265 year to date | $42,269 for Q3 2022; $380,789 for nine months 2022 |
| Gross profit (loss) | $(13,730) for Q3; $(12,566) year to date | $31,528 for Q3 2022; $359,785 for nine months 2022 |
| Operating expenses | $2,141,143 for Q3; $6,242,333 year to date | $3,747,369 for Q3 2022; $12,341,207 for nine months 2022 |
| Net loss | $(3,368,080) for Q3; $(7,580,535) year to date | $(3,776,524) for Q3 2022; $(11,811,472) for nine months 2022 |
| Loss per share, basic and diluted | $(0.82) for Q3; $(2.08) year to date | $(1.14) for Q3 2022; $(3.71) for nine months 2022 |
| Cash from operations | $(3,756,385) year to date | $(6,937,322) year to date 2022 |
| Cash and restricted cash | $1,120,937 total; includes $500,069 unrestricted cash | $1,391,728 at Dec. 31, 2022 |
| Working capital | $(2,869,542) deficit | $(2,556,381) deficit at Dec. 31, 2022 |
| Total assets / total liabilities | $16,591,507 / $7,529,911 | $9,579,574 / $6,343,435 at Dec. 31, 2022 |
Year-to-date revenue fell about 61% year over year, and gross profit turned to a loss. Management attributed lower revenue to completed projects and waiting for new approvals. Operating expenses fell about 49%, primarily with lower SG&A, R&D and non-employee stock compensation. Net loss narrowed about 36%, but interest expense rose to $1,390,039 year to date from $159,507, substantially offsetting lower operating costs. Q3 interest expense was $1,218,624.
At September 30, listed borrowings included $852,500 of short-term bank loans and $1,654,004 carrying value of third-party convertible notes. Current liabilities were $5,363,076; lease liabilities totaled approximately $899,817. Financing cash flows were $3,831,540, including stock issuance, warrant proceeds and convertible-note proceeds. The filing states substantial doubt about the Company’s ability to continue as a going concern, citing recurring losses, a working-capital deficit and operating cash outflows. Management plans to improve operations and seek additional capital.
Material changes, outlook and risks
- Funding and dilution: The February 2023 Lind financing included a secured convertible note with $3,704,167 principal, issued for $3,175,000, and a warrant. Lind may convert at adjusted terms; monthly repayments may be made in cash or stock. A September amendment reduced the default amount to 115% of outstanding principal and waived a market-capitalization-related default through February 23, 2024, but conversion rights remain. The Company warned a future default could materially harm liquidity. After quarter-end, it reported issuing Lind 2,329,495 shares for $1,572,600; 7,231,940 shares were outstanding as of November 9.
- Pipeline and clinical risk: The Vitargus Phase II study in Thailand was placed on hold after serious adverse events in patients treated with either Vitargus or the comparator. The Company is investigating causes and developing a safer procedure before resuming the study. ABV-1505 ADHD Phase II Part II and ABV-1601 depression-in-cancer Phase I are among the other clinical programs described. No quantified financial guidance is provided.
- Property transaction: ABVC recorded a 20% interest in a China property at $7.4 million in exchange for 370,000 shares valued at $20 per share. Government asset-ownership certification remained pending; the parties plan to develop a healthcare center, with construction targeted for completion before the end of 2024.
- Subsequent licensing announcements: In November 2023, ABVC and BioLite each entered into global licensing agreements with AIBL for CNS products. Each is to receive 23 million AIBL shares stated at $10 per share; additional $3.5 million payments and 5% royalties, capped at $100 million, depend on milestones. These are forward-looking contractual terms, not reported quarter-end cash proceeds.
- Concentration and related parties: One customer accounted for 81.19% of nine-month revenue and 99.76% of accounts receivable at September 30. The Company also reported material balances and arrangements with related parties, including loans and amounts due from Rgene and BioFirst-related entities.
- Accounting, controls and listing: The Company determined goodwill was impaired due to its financial condition and uncertain future operating cash flows; the filing text does not provide a clear impairment amount. Management said disclosure controls were ineffective as of September 30 because of a previously reported material weakness. The Company reported meeting Nasdaq’s stockholders’ equity requirement as of August 31, but said Nasdaq would continue monitoring compliance. Its reverse split was intended to help restore listing compliance; the filing does not guarantee that outcome.
Investor facts to verify
- How management plans to fund operations and address the going-concern conditions, including the timing and terms of any additional financing.
- The remaining Lind note balance, conversion and repayment activity, dilution exposure, and compliance with the amended default waiver.
- The status of the Vitargus safety investigation and whether clinical development can resume; also verify enrollment and regulatory progress across other trials.
- Whether the China property ownership certification is obtained and how the $7.4 million valuation and development plan are substantiated.
- The terms, enforceability, milestone conditions and actual deliverables under the AIBL licensing agreements, including the valuation and liquidity of the promised shares.
- Reconcile equity figures: the balance sheet reports total equity of $9,061,596, while MD&A cites stockholders’ equity of $7,548,308 at September 30; the filing text does not clearly reconcile these amounts.
- Assess the customer and related-party concentration, collectability of related-party receivables, and progress in remediating the disclosed control weakness.